The rationale for immunomodulation is biologically plausible. In herpes simplex virus encephalitis, much of the neurological damage is attributed not only to direct viral cytolysis but also to the host immune response, including cytokine release, edema, and secondary inflammatory cascades that can extend injury well beyond infected neurons. Corticosteroids, by suppressing this inflammation, could in theory reduce swelling, limit tissue damage, and improve outcomes. The idea is not new; discussions of dexamethasone in herpes simplex encephalitis appeared in the medical literature as early as the 1970s, and the approach has been incorporated into some clinical guidelines as an option for patients with life-threatening cerebral edema. Yet the clinical evidence base has remained fragmented, small, and methodologically uneven.

To resolve the uncertainty, Zhang and colleagues searched PubMed/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from their inception through 4 July 2026, and also examined trial registries and reference lists of relevant publications. They included randomized controlled trials and comparative observational studies that evaluated systemic corticosteroids added to background antiviral therapy against the same antiviral therapy alone or with placebo. Acyclovir was the background antiviral agent in every study that specified the regimen, ensuring that the comparison isolated the effect of the steroid rather than differences in antiviral care. The co-primary outcomes were study-defined unfavorable global neurological or functional outcome and all-cause mortality, with secondary endpoints covering serious adverse events, seizures during follow-up, cognition, persistent herpes simplex virus DNA in cerebrospinal fluid, relapse, and functional independence measured by the Barthel Index.

The yield from more than five decades of literature was strikingly thin. Only four comparative studies, encompassing 209 patients, met the inclusion criteria: two randomized trials and two retrospective studies. The randomized trials were pooled using Mantel-Haenszel random-effects methods for risk ratios, while mean differences were combined with inverse-variance random-effects approaches. Because non-randomized treatment allocation introduces substantial clinical heterogeneity and confounding by indication, the observational evidence was analyzed and interpreted separately from the randomized data, a decision that reflects contemporary standards for evidence synthesis.

The pooled results from the randomized trials were uniformly inconclusive. For unfavorable global outcome, the pooled risk ratio was 1.00 with a 95 percent confidence interval of 0.68 to 1.47, a point estimate of exactly no effect flanked by intervals wide enough to accommodate both meaningful benefit and meaningful harm. Mortality showed a risk ratio of 0.92 (95 percent confidence interval 0.35 to 2.40), serious adverse events a risk ratio of 1.14 (95 percent confidence interval 0.54 to 2.44), and seizures during follow-up a risk ratio of 0.73 (95 percent confidence interval 0.33 to 1.62). None of these estimates approached conventional thresholds for statistical significance, and all were imprecise, reflecting the small number of patients contributing to each analysis.

Functional and cognitive endpoints fared no better. Barthel Index scores, a standard measure of activities of daily living, showed a mean difference of 3.05 points (95 percent confidence interval, minus 6.99 to 13.09) at approximately six months and 0.30 points (95 percent confidence interval, minus 13.84 to 14.45) at discharge or day 30, differences that are clinically negligible and statistically indistinguishable from zero. Cognitive findings across studies were not consistently favorable. In short, on every endpoint the meta-analysis examined, the randomized evidence could neither confirm benefit nor exclude harm, a pattern the authors attribute to the limited and imprecise nature of the underlying data rather than to demonstrated equivalence.

The observational studies added little clarity and, in some respects, raised concerns. Their estimates conflicted with one another and were judged to be seriously compromised by confounding, since clinicians tend to give steroids to the sickest patients, biasing any naive comparison. The randomized trials did, however, generate two signals worth noting. In the DexEnceph trial, a multicenter, observer-blind, phase 3 study of adjunct dexamethasone in adults with herpes simplex virus encephalitis conducted in the United Kingdom, herpes simplex virus DNA remained detectable in cerebrospinal fluid at approximately day 14 in 4 of 36 dexamethasone recipients compared with 9 of 43 controls, a numerical difference of uncertain significance. More strikingly, five relapses were reported among dexamethasone-treated patients and none among controls, although the authors caution that so few events do not permit a causal conclusion. The possibility that corticosteroid-induced immunosuppression might prolong viral clearance or provoke relapse has long been a theoretical worry, and these findings keep it alive without settling it.

The meta-analysis also highlights a critical gap. The one scenario in which corticosteroids are most often deployed in practice, life-threatening cerebral edema with impending herniation, was never specifically evaluated in any included study. The evidence is therefore insufficient to determine whether steroids help or harm this selected subgroup, leaving clinicians to make high-stakes decisions on physiological reasoning alone. The authors call for future adequately powered, multicenter randomized trials that use standardized treatment protocols and prespecify severity- and edema-defined subgroups, so that the question of immunomodulation can be answered separately for the broad population and for the narrow emergency indication.

For now, the practical message is one of restraint. With roughly 209 randomized and comparative patients studied across half a century, the field has generated data too sparse to justify routine adjunctive corticosteroids, yet too imprecise to close the door entirely. Clinicians managing herpes simplex virus encephalitis should continue to prioritize early acyclovir, the intervention with proven mortality benefit, and reserve corticosteroids for circumstances where cerebral edema threatens immediate deterioration, ideally within the framework of clinical trials or prospective registries. The new synthesis in the Journal of Neurology does not declare steroids useless; it declares the question still open, and in doing so it sets a clear agenda for the trials the field has, until now, failed to deliver.

Subject of Research: Adjunctive corticosteroid therapy for herpes simplex virus encephalitis

Article Title: Adjunctive corticosteroids in herpes simplex virus encephalitis: a meta-analysis of randomized and observational studies

Article References: Zhang, D., Yang, M., Huang, Y., Liang, M., Yao, L., Liang, J., Deng, M., & Shen, R. (2026). Adjunctive corticosteroids in herpes simplex virus encephalitis: a meta-analysis of randomized and observational studies. Journal of Neurology, 273(10), Article 567. https://doi.org/10.1007/s00415-026-14128-x

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14128-x

Keywords: herpes simplex virus encephalitis, corticosteroids, dexamethasone, acyclovir, meta-analysis, neurological outcome, cerebral edema, randomized controlled trials, Barthel Index, relapse, cerebrospinal fluid HSV DNA, Journal of Neurology

Herpetic whitlow results when herpes simplex virus, most commonly herpes simplex virus type 1, inoculates the skin of a digit through a break in the cutaneous barrier. The virus travels to sensory nerve endings, establishes infection in the distal phalanx, and produces one or more intensely painful vesicles that may coalesce into a larger blister resembling a bacterial felon or paronychia. The infection classically affects the thumb and index finger, though any digit may be involved. In children, autoinoculation from thumb-sucking or finger-sucking during oral herpetic infections is the dominant route of acquisition, while in adults the disease has historically been an occupational hazard among dentists, dental hygienists, and other health care workers exposed to oral secretions before the widespread adoption of gloves.

The historical record captured in the review begins with early observations that established whitlow as a nosocomial threat. Among the foundational works cited is a 1959 Lancet study by Stern and colleagues describing herpetic whitlow as a form of cross-infection in hospitals, a report that helped define the condition’s public health significance at a time when its viral etiology was still being separated from pyogenic infections of the hand. By the end of the twentieth century, larger clinical series such as the 1990 analysis by Gill and colleagues of herpes simplex virus infection of the hand, published in the Journal of the American Academy of Dermatology, had clarified the spectrum of disease in adults and children alike, documenting incubation periods, recurrence patterns, and the substantial morbidity that recurrent infection imposes on patients.

The technical groundwork for the present synthesis rests on several strands of evidence. Case reports of pediatric whitlow, exemplified by the 2001 European Journal of Pediatrics report by Szinnai and colleagues describing multiple herpetic whitlow lesions in a four-year-old girl, illustrate how extensive the lesions can become in young children and how easily the presentation can be mistaken for more common blistering disorders. Occupational case series, including the 2012 report by Browning and McCarthy in the Journal of Esthetic and Restorative Dentistry documenting herpes simplex virus as an occupational hazard among dental practitioners, reinforce the role of exposure routes in shaping who develops the disease. On the therapeutic side, the pharmacological understanding of nucleoside analogs such as acyclovir and its relatives has matured considerably, as summarized in the 2022 PharmGKB review by Maillard and colleagues of the acyclovir and ganciclovir metabolic pathway, which maps how these prodrugs are converted by viral and cellular thymidine kinases into active triphosphate forms that selectively inhibit viral DNA polymerase.

By pooling published case material, the Weill Cornell-led team sought to define the epidemiological and clinical profile of herpetic whitlow with more precision than any single case report could provide. The review’s design reflects a growing appreciation in dermatology that rare or underrecognized conditions accumulate meaningful evidence only when scattered reports are aggregated and analyzed together. The researchers coordinated the project across four institutions, with Vijayvargiya responsible for data collection, Vijayvargiya and Zhou performing the analysis and drafting, Singal contributing to conception, design, and revision, and Lipner overseeing the work and providing final approval. The authors declared no competing interests and reported no external funding for the study, and the paper was accepted on 1 September 2026 and published on 12 September 2026 in volume 318 of the journal.

The clinical importance of distinguishing herpetic whitlow from bacterial infections of the hand cannot be overstated. Misdiagnosis as a bacterial felon or paronychia has historically led to incision and drainage, a surgical intervention that is not only unnecessary for viral infection but potentially harmful, because breaching the skin can introduce secondary bacterial infection or delay appropriate antiviral therapy. Recognizing the characteristic morphology of whitlow, grouped vesicles on an erythematous base with a predilection for the distal phalanx, along with a history of prior oral or genital herpes lesions, exposure to oral secretions, or recent trauma to the digit, allows clinicians to avoid inappropriate surgery and initiate antiviral treatment promptly. Diagnostic confirmation, when needed, can be achieved through viral culture, polymerase chain reaction testing, or Tzanck smear, though the classic presentation in most cases permits clinical diagnosis.

Therapy for herpetic whitlow rests on antiviral agents, principally acyclovir, valacyclovir, and famciclovir, which shorten the duration of viral shedding and accelerate healing when initiated early in the course of infection. The pharmacogenetic pathway described by Maillard and colleagues explains both the selectivity and the limitations of these drugs: acyclovir is preferentially phosphorylated by virus-encoded thymidine kinase, concentrating active drug in infected cells, but resistance can emerge in immunocompromised patients through loss or alteration of the viral kinase, in which case drugs with alternative mechanisms, such as foscarnet, may be required. For immunocompetent patients, most episodes resolve spontaneously within two to four weeks, though recurrent disease can be frequent, painful, and disruptive, particularly for health care workers whose livelihoods depend on unimpaired hand function.

Prevention strategies highlighted across the reviewed literature emphasize simple but effective measures. The dramatic decline in occupational whitlow among dental professionals after routine gloving became standard practice stands as one of the clearest demonstrations that barrier precautions control transmission of herpes simplex virus in clinical settings. In households, parents and caregivers with active oral herpes lesions can reduce transmission to children by avoiding kissing children on or near the mouth, not sharing utensils and towels, and discouraging thumb-sucking in children with active herpetic gingivostomatitis. People with recurrent whitlow can reduce autoinoculation risk by avoiding contact between their lesions and other body sites, particularly the eyes, where herpes infection can threaten vision.

The consolidated picture that emerges from this review serves a dual purpose. For clinicians, it provides an evidence-based reference point for recognizing a condition that, despite its distinctive appearance, continues to be misdiagnosed in emergency departments, pediatric clinics, and dermatology practices. For researchers, it identifies gaps in the literature, including the relative scarcity of prospective studies and randomized treatment trials in both children and adults, since most of the evidence base remains built on individual case reports and small series. As antiviral pharmacology advances and awareness of occupational and household transmission routes deepens, syntheses of the kind now published by the Weill Cornell, Rutgers, and Columbia collaboration help ensure that the accumulated clinical wisdom of six decades of case reporting is not lost but translated into better diagnosis, more judicious treatment, and fewer preventable infections of the hand.

Subject of Research: Herpetic whitlow: a systematic review of published herpes simplex virus infection cases of the fingers

Article Title: Review of published herpetic whitlow cases

Article References: Vijayvargiya, N., Singal, A., Zhou, M. H., & Lipner, S. R. (2026). Review of published herpetic whitlow cases. Archives of Dermatological Research, 318(1), Article 412. https://doi.org/10.1007/s00403-026-04923-x

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04923-x

Keywords: herpetic whitlow, herpes simplex virus, dermatology, acyclovir, occupational infection, pediatric herpes, antiviral therapy, nail and hand infection, case report review, viral infection, dental health workers, autoinoculation